Data presented at ACG Annual Scientific Meeting

RNS Number : 7582D

Shield Therapeutics PLC

24 October 2022

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

Shield Presents Data at ACG Annual Scientific Meeting 2022 on Accrufer®

London, UK, 24 October 2022:  Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces that a pooled analysis from ferric maltol clinical trials will be presented at the American College of Gastroenterology Annual Scientific Meeting (ACG 2022). ACG 2022 is underway, virtually and in-person, and runs through to 26 October 2022 in Charlotte, North Carolina, USA.

The abstract is available online in the ACG 2022 Abstract Guide: https://acgmeetings.gi.org/

Shield Therapeutics Poster Presentation Details:

Poster:	D0361
Title:	" A pooled analysis of early and sustained response in patients with Inflammatory Bowel Disease (IBD) with Iron Deficiency Anemia (IDA) who were treated with ferric maltol"
Date:	25 October 2022
Time:	10:00AM - 12:00PM ET

ACG 2022 is one of the most prestigious gastrointestinal (GI) clinical conferences, bringing together GI physicians and providing them with the opportunity to network with peers, share experiences from their practice, learn the latest clinical information on key GI topics, and see the latest advances in GI technology and therapeutics throughout the conference.

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Greg Madison, CEO	[phone]
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Christopher Golden	[phone]
Joint Broker finnCap Ltd  Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks	[phone]
Financial PR & IR Advisor
Walbrook PR
Lianne Applegarth/Alice Woodings	[phone] or  [e-mail]
Investor Contact (US Advisor) LifeSci Advisors, LLC John Mullaly	[phone] or [e-mail]

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

 

END

 

 

NRABDBDGCUDDGDB